STADA Arzneimittel AG (ETR:SAZ) has been given an average recommendation of “Sell” by the six brokerages that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation and two have given a hold recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is €74.08 ($91.45).
Several equities research analysts have weighed in on the company. Nord/LB set a €74.40 ($91.85) target price on STADA Arzneimittel and gave the stock a “sell” rating in a report on Wednesday, December 20th. Warburg Research set a €74.40 ($91.85) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a research note on Wednesday, December 20th. Independent Research set a €89.00 ($109.88) price objective on STADA Arzneimittel and gave the stock a “neutral” rating in a research note on Wednesday, December 20th. Commerzbank set a €66.25 ($81.79) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a research note on Tuesday, December 26th. Finally, S&P Global set a €74.40 ($91.85) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a research note on Friday, November 10th.
Shares of STADA Arzneimittel (SAZ) opened at €86.42 ($106.69) on Thursday. STADA Arzneimittel has a 1-year low of €53.41 ($65.94) and a 1-year high of €90.24 ($111.41). The firm has a market capitalization of $5,350.00 and a price-to-earnings ratio of 56.86.
COPYRIGHT VIOLATION NOTICE: “STADA Arzneimittel AG (SAZ) Given Average Rating of “Sell” by Brokerages” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/22/stada-arzneimittel-ag-saz-given-average-rating-of-sell-by-brokerages.html.
About STADA Arzneimittel
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.